 BioVac-19 is a novel vaccine being developed against COVID-19. It is based on the premise that the virus's spike protein contains non-human, like NHL, epitopes that can elicit an effective immune response. These epitopes have been identified through empirical analysis of the virus's structure and behavior, as well as past experiences with HIV and SARS. The vaccine also takes advantage of the virus's ability to bind to the angiotensin converting enzyme 2, ACE2, receptor, but does not rely solely on this interaction. Instead, it uses a combination of receptor-mediated and non-receptor-mediated mechanisms to induce an immune response. This article was authored by Burgess Rensen, Andresses Rood, and Angus George D'Aublish.